RXRX RECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 6.16 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:47:05 EDT
QQQ $ 591.86 $ 0.00 (0 %)
DIA $ 455.60 $ 0.00 (0 %)
SPY $ 653.08 $ 0.00 (0 %)
TLT $ 91.51 $ 0.00 (0 %)
GLD $ 399.68 $ 0.00 (0 %)
$ 6.36
$ 6.80
$ 6.16 x 350
$ 6.16 x 1,450
-- - --
$ 3.79 - $ 12.36
229,692,510
na
2.76B
$ 2.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 costco-amd-recursion-pharmaceuticals-cipher-mining-and-snowflake-why-these-5-stocks-are-on-investors-radars-today

On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&P 500 slipping nearly 0.6...

 whats-going-on-with-recursion-pharmaceuticals-stock-on-wednesday

Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

 jim-cramer-says-this-financial-stock-is-a-total-spec-likes-dutch-bros

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-8-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

 recursion-pharmaceuticals-reports-wider-than-expected-q2-loss-beats-revenue-estimates

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga...

 palantir-nvidia--tempus-ai-could-be-pharma-etf-darlings-that-dont-make-pills

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still...

 how-palantir-tempus-nvidia-backed-recursion-are-disrupting-big-pharma

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma...

 why-is-recursion-pharma-stock-surging-on-monday

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpect...

 recursion-pharmaceuticals-posts-on-x-in-an-industry-where-over-90-of-drug-candidates-fail-we-are-relentlessly-working-to-find-a-better-way-to-discover-and-develop-new-medicines-a-new-feature-in-wired-from-verogreenwood-captures-the-high-stakes-world-of-drug-discovery-highlighting-the-progress-were-making-and-the-patients-who-inspire-our-work-

https://x.com/RecursionPharma/status/1946189113138229690

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION